The efficacy and safety of combined 0.01% atropine and orthokeratology for childhood myopia control: a 2-year randomized clinical trial

1

The study evaluated the efficacy and safety of low-concentration atropine combined with orthokeratology for myopia management in children.
2

Over 24 months, the AOK group showed significantly slower axial elongation compared to the OK group, with measurements of 0.33 mm vs. 0.43 mm.
3

Subgroup analysis indicated significant differences in axial length changes for children aged 8-10 years and those with initial SER of -1.00 to -3.00D.
4

At 24 months, secondary outcomes like TMH, NIBUT, visual acuity, and pupil size were similar between AOK and OK groups, with longer pupillary light reflex latency in AOK.
5

The combination therapy demonstrated good tolerability and minimal impact on ocular surfaces, highlighting its potential as a myopia control strategy.

1